IOP lowered with trab and combination trab

Article

IOP is successfully reduced with both trabeculectomy and combined trabeculotomy-trabeculectomy with mitomycin C in children with glaucoma.

IOP is successfully reduced with both trabeculectomy and combined trabeculotomy-trabeculectomy with mitomycin C in children with glaucoma.

The retrospective, comparative study, led by Dr Peter A. Netland, Department of Ophthalmology (SDL), University of North Carolina, Chapel Hill, North Carolina, USA, included 40 eyes of 33 glaucoma patients.

Trabeculectomy was performed on 17 eyes (Group 1) and 23 eyes underwent combined trabeculotomy-trabeculectomy (Group 2), with mitomycin C administered to all patients. Successful surgery was defined if IOP was 21 mmHg or less and greater than 5 mmHg without additional surgery.

No significant difference in mean IOP reduction was found between the groups during follow-up. There was a higher success rate after surgery in group 2, compared to group 1. There were five treatment failures in group 1 and two in group 2. The failures were caused increased IOP or hypotony and there were no complications observed.

Both procedures are equally effective in lowering average IOP in children with glaucoma, but combined trabeculotomy-trabeculectomy was linked to greater long-term successful outcomes.

More detailed information may be found at the Journal of Paediatric Ophthalmology and Strabismus, click here

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.